Will statins be used in dementia treatment?;Czy statyny znajda zastosowanie w leczeniu otepienia?

Neurologia i Neurochirurgia Polska

Volumn 39, Issue 4, 2005, Pages 318-323

  Wehr, Hanna ^a   Bednarska Makaruk, Małgorzata ^a  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Cholesterol; Dementia; Pleiotropic effects of statins; Statins

Indexed keywords

AMYLOID BETA PROTEIN; ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEVINOLIN; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; SIMVASTATIN;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CHOLESTEROL SYNTHESIS; COGNITION; DEMENTIA; DRUG MECHANISM; HUMAN; INFLAMMATION; PATHOGENESIS; PRENYLATION; PROTEIN MODIFICATION; REVIEW;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ENDOPEPTIDASES; CHOLESTEROL; CYTOCHROME P-450 ENZYME SYSTEM; DEMENTIA, VASCULAR; ENDOPEPTIDASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NITRIC OXIDE SYNTHASE; PPAR GAMMA;

EID: 23944508031     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999; 399: A23-A31.
2. Taylor J.P., Hardy J., Fischbeck K.H. Toxic proteins in neurodegenerative diseases. Science 2002; 296: 1991-1995.
3. Atkinson J. Cerebrovascular structure and dementia: new drug targets. Trends Pharmacol Sci 2001; 22: 630-635.
4. Simons M., Keller P., Dichgans J. i wsp. Cholesterol and Alzheimer's disease: is there a link? Neurology 2001; 57: 1089-1093.
5. Kojro E., Gimpl L., Lammich S. i wsp. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci USA 2001; 98: 5815-5820.
6. Notkola I.L., Sulkava R., Pekkanen J. i wsp. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998; 17: 14-20.
7. Kuo Y.M., Emmerling M.R., Bisgaier C.L. i wsp. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain Aβ 1-42 levels. Biochem Biophys Res Commun 1998; 252: 711-715.
8. Kivipelto M., Helkala E.L., Laakso M.P. i wsp. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447-1451.
9. Tan Z.S., Seshadri S., Beiser A. i wsp. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch Intern Med 2003; 163: 1053-1057.
10. Piguet O., Grayson D.A., Creasey H. i wsp. Vascular risk factors, cognition and dementia incidence over 6 years in the Sydney Older Persons Study. Neuroepidemiology 2003; 22: 165-171.
11. Sparks D.L., Martins R., Martin T. Cholesterol and cognition: rationale for the AD cholesterol-lowering treatment trial and sex-related differences in beta-amyloid accumulation in the brains of spontaneously hypercholesterolemic Watanabe rabbits. Ann NY Acad Sci 2002; 977: 356-366.
12. Shie F.S., Jin L.W., Cook D.G. i wsp. Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport 2002; 13: 455-459.
13. Dietschy J.M., Turley S.D. Cholesterol metabolism in the brain. Curr Opin Lipidol 2001; 12: 105-112.
14. Schonknecht P., Lutjohann D., Pantel J. i wsp. Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neurosci Lett 2002; 324: 83-85.
15. Gibson Wood W, Eckert G.P., Igbavboa U. i wsp. Amyloid beta-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease. Biochim Biophys Acta 2003; 1610: 281-290.
16. Hayashi H., Igbavboa U., Hamanaka H. i wsp. Cholesterol is increased in the exofacial leaflet of synaptic plasma membranes of human apolipoprotein E4 knock-in mice. Neuroreport 2002; 13: 383-386.
17. Chong P.H., Seeger J.D., Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 2001; 111: 390-400.
18. Lennernas H., Eager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997; 32: 403-425.
19. Hamelin B.A., Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998; 19: 26-37.
20. Evans M., Rees A. The myotoxicity of statins. Curr Opin Lipidol 2002; 13: 415-420.
21. Wolozin B., Kellman W., Ruosseau P. i wsp. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439-1443.
22. Jick H., Zornberg G.L., Jick S.S. i wsp. Statins and the risk of dementia. Lancet 2000; 356: 1627-1631.
23. Simons M., Schwarzler F., Lutjohann D. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002; 52: 346-350.
24. Fassbender K., Simons M., Bergmann C. i wsp. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ 42 and Aβ 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 5856-5861.
25. Birkenhager W.H., Wang J.G., Staessen J.A. Dementia and statins. Lancet 2001; 357: 880.
26. Etminan M., Gill S., Samii A. The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy 2003; 23: 726-730.
27. Locatelli S., Luetjohann D., Schmidt H.H.J. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin effects cholesterol metabolism in the human brain. Arch Neurol 2002; 59: 213-216.
28. Santanello N.C., Barber B.L., Applegate W.B. i wsp. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J Am Geriatr Soc 1997; 45: 8-14.
29. Muldoon M.F., Barger S.D., Ryan C.M. i wsp. Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000; 108: 538-546.
30. Petanceska S.S., DeRosa S., Olm V. i wsp. Statin therapy for Alzheimer's disease: will it work? J Mol Neurosci 2002; 19: 155-161.
31. Rockwood K., Kirkland S., Hogan D.B. i wsp. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002; 59: 223-227.
32. Wagstaff L.R., Mitton M.W., Arvik B.M. i wsp. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003; 23: 871-880.
33. Kirsch C., Eckert G.P., Mueller W.E. Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem Pharmacol 2003; 65: 843-856.
34. Laufs U., Liao J.K. Post-transcriptonal regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273: 24266-24271.
35. Kureishi Y., Luo Z., Shiojima I. i wsp. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 1004-1010.
36. Cucchiara B., Kasner S.E. Use of statins in CNS disorders. J Neurol Sci 2001; 187: 81-89.
37. Crisby M., Carlson L.A., Winblad B. Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2002; 16: 131-136.
38. Stuve O., Youssef S., Steinman L. i wsp. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol 2003; 16: 393-401.
39. Vaughan C.J., Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999; 30: 1969-1973.
40. Zelvyte I., Dominaitiene R., Crisby M. i wsp. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 2002; 45: 147-154.
41. Giroux L.M., Davignon J., Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1993; 1165: 335-338.
42. Inoue T., Hayashi M., Takayanagi K. i wsp. Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients. Atherosclerosis 2002; 160: 369-376.
43. Orem C., Orem A., Uychi H.A. i wsp. The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status. Coron Artery Dis 2002; 13: 65-71.
44. Chen L., Haught H., Yang B. i wsp. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol 1997; 30: 569-575.
45. Deakin S., Leviev I., Guernier S. i wsp. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol 2003; 23: 2083-2089.
46. Darvesh S., Martin E., Walsh R. i wsp. Differential effects of lipid-lowering agents on human cholinesterases. Clin Biochem 2004; 37: 42-49.
47. Maron D.J., Fazio S., Linton M.F. Current perspectives on statins. Circulation 2000; 101: 207-213.
48. Gaist D., Jeppesen U., Andersen M. i wsp. Statins and risk of polyneuropathy: a case-control study. Neurology 2002; 58: 1333-1337.
49. Meske V., Albert F., Richter D. i wsp. Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease. Eur J Neurosci 2003; 17: 93-102.
50. Austen B., Christodoulou G., Terry J.E. Relation between cholesterol levels, statins and Alzheimer's disease in the human population. J Nutr Health Aging 2002; 6: 377-382.
51. Doraiswamy P.M. Non-cholinergic strategies for treating and preventing Alzheimer's disease. CNS Drugs 2002; 16: 811-824.
52. Heuser I. Prevention of dementias: state of the art. Dtsch Med Wochenschr 2003; 128: 421-422.
53. Vaughan C.J. Prevention of stroke and dementia with statins: effects beyond lipid lowering. Am J Cardiol 2003; 91 (suppl.): 23B-29B.
54. Waldman A., Kritharides L. The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia. Drugs 2003; 63: 139-152.
55. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo controlled trial. Lancet 2002; 360: 7-22.
56. Shepherd J., Blauw G.J., Murphy M.B. i wsp. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002; 360: 1623-1630.
57. Li G., Higdon R., Kukull W.A. i wsp. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004; 63: 1624-1628.
58. Zandi P. p., Sparks D.L., Khachaturian A.S. i wsp. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 2005; 62: 217-224.